Determinants of influenza vaccination uptake in pregnancy: a large single-Centre cohort study.


Journal

BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799

Informations de publication

Date de publication:
19 Dec 2019
Historique:
received: 20 06 2018
accepted: 22 11 2019
entrez: 21 12 2019
pubmed: 21 12 2019
medline: 2 6 2020
Statut: epublish

Résumé

Although vaccination of pregnant women against influenza is recommended, the vaccination rate remains low. We conducted a study to identify determinants of influenza vaccination uptake in pregnancy in order to identify strategies to improve seasonal influenza vaccination rates. Prospective observational hospital-based study in the French hospital performing the highest number of deliveries, located in the city of Lille, among all women who had given birth during the 2014-2015 influenza season. Data were collected through a self-completed questionnaire and from medical files. The vaccination uptake was self-reported. Determinants of vaccination uptake were identified using logistic regression analysis. Of the 2045 women included in the study, 35.5% reported that they had been vaccinated against influenza during their pregnancy. The principal factors significantly associated with greater vaccination uptake were previous influenza vaccination (50.9% vs 20.2%, OR 4.1, 95% CI 3.1-5.5), nulliparity (41.0% vs 31.3%, OR 2.5, 95% CI 1.7-3.7), history of preterm delivery < 34 weeks (43.4% vs 30.3%, OR 2.3, 95% CI 1.1-4.9), the mother's perception that the frequency of vaccine complications for babies is very low (54.6% vs 20.6%, OR 1.1, 95% CI 0.5-2.2), the mother's good knowledge of influenza and its vaccine (61.7% vs 24.4%, OR 3.1, 95% CI 2.2-4.4), hospital-based prenatal care in their first trimester of pregnancy (55.0% vs 30.2%, OR 2.1, 95% CI 1.2-3.7), vaccination recommendations during pregnancy by a healthcare worker (47.0% vs 2.7%, OR 18.8, 95% CI 10.0-35.8), receipt of a vaccine reimbursement form (52.4% vs 18.6%, OR 2.0, 95% CI 1.5-2.7), and information from at least one healthcare worker about the vaccine (43.8% vs 19.1%, OR 1.8, 95% CI 1.3-2.6). Our findings suggest that in order to increase flu vaccination compliance among pregnant women, future public health programmes must ensure cost-free access to vaccination, and incorporate education about the risks of influenza and the efficacy/safety of vaccination and clear recommendations from healthcare professionals into routine antenatal care.

Sections du résumé

BACKGROUND BACKGROUND
Although vaccination of pregnant women against influenza is recommended, the vaccination rate remains low. We conducted a study to identify determinants of influenza vaccination uptake in pregnancy in order to identify strategies to improve seasonal influenza vaccination rates.
METHODS METHODS
Prospective observational hospital-based study in the French hospital performing the highest number of deliveries, located in the city of Lille, among all women who had given birth during the 2014-2015 influenza season. Data were collected through a self-completed questionnaire and from medical files. The vaccination uptake was self-reported. Determinants of vaccination uptake were identified using logistic regression analysis.
RESULTS RESULTS
Of the 2045 women included in the study, 35.5% reported that they had been vaccinated against influenza during their pregnancy. The principal factors significantly associated with greater vaccination uptake were previous influenza vaccination (50.9% vs 20.2%, OR 4.1, 95% CI 3.1-5.5), nulliparity (41.0% vs 31.3%, OR 2.5, 95% CI 1.7-3.7), history of preterm delivery < 34 weeks (43.4% vs 30.3%, OR 2.3, 95% CI 1.1-4.9), the mother's perception that the frequency of vaccine complications for babies is very low (54.6% vs 20.6%, OR 1.1, 95% CI 0.5-2.2), the mother's good knowledge of influenza and its vaccine (61.7% vs 24.4%, OR 3.1, 95% CI 2.2-4.4), hospital-based prenatal care in their first trimester of pregnancy (55.0% vs 30.2%, OR 2.1, 95% CI 1.2-3.7), vaccination recommendations during pregnancy by a healthcare worker (47.0% vs 2.7%, OR 18.8, 95% CI 10.0-35.8), receipt of a vaccine reimbursement form (52.4% vs 18.6%, OR 2.0, 95% CI 1.5-2.7), and information from at least one healthcare worker about the vaccine (43.8% vs 19.1%, OR 1.8, 95% CI 1.3-2.6).
CONCLUSIONS CONCLUSIONS
Our findings suggest that in order to increase flu vaccination compliance among pregnant women, future public health programmes must ensure cost-free access to vaccination, and incorporate education about the risks of influenza and the efficacy/safety of vaccination and clear recommendations from healthcare professionals into routine antenatal care.

Identifiants

pubmed: 31856752
doi: 10.1186/s12884-019-2628-5
pii: 10.1186/s12884-019-2628-5
pmc: PMC6924067
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

510

Références

Presse Med. 2013 Nov;42(11):1453-60
pubmed: 23683385
Obstet Gynecol Sci. 2015 Mar;58(2):81-9
pubmed: 25798420
Vaccine. 2009 Mar 26;27(15):2114-20
pubmed: 19356614
N Engl J Med. 2014 Sep 4;371(10):918-31
pubmed: 25184864
PLoS Curr. 2015 Feb 25;7:
pubmed: 25789203
J Obstet Gynaecol Can. 2009 Feb;31(2):120-5
pubmed: 19327210
Vaccine. 2016 Apr 29;34(20):2390-6
pubmed: 27013430
BMC Public Health. 2019 Jul 5;19(1):890
pubmed: 31277611
N Engl J Med. 2008 Oct 9;359(15):1555-64
pubmed: 18799552
Obstet Gynecol. 2010 Oct;116(4):949-955
pubmed: 20859160
Hum Vaccin Immunother. 2019;15(3):687-699
pubmed: 30380986
Obstet Gynecol. 2014 Sep;124(3):648-651
pubmed: 25162283
MMWR Morb Mortal Wkly Rep. 2017 Sep 29;66(38):1016-1022
pubmed: 28957044
N Engl J Med. 2010 Apr 29;362(17):1644-6
pubmed: 20427817
Vaccine. 2016 Aug 17;34(37):4443-9
pubmed: 27449682
J Matern Fetal Neonatal Med. 2012 Sep;25(9):1800-9
pubmed: 22339083
Vaccine. 2014 Aug 6;32(36):4602-13
pubmed: 24996123
Obstet Gynecol. 2018 May;131(5):799-802
pubmed: 29630014
J Gynecol Obstet Hum Reprod. 2017 Dec;46(10):701-713
pubmed: 29031048
Vaccine. 2015 Nov 25;33(47):6420-9
pubmed: 26320417
Arch Pediatr. 2018 May;25(4):245-246
pubmed: 29656826
Vaccine. 2016 Aug 17;34(37):4450-9
pubmed: 27452865
Vaccine. 2013 Nov 12;31(47):5557-64
pubmed: 24076176

Auteurs

Stéphanie Bartolo (S)

University Lille, EA 2694 : épidémiologie et qualité des soins, pôle recherche aile Est 2ème étage, 59 045 cedex, 1 Place de Verdun, 59 000, Lille, France. stephanie.bartolo@gmail.com.
Douai hospital, route de Cambrai, -, 10740 - 59507, Douai Cedex, BP, France. stephanie.bartolo@gmail.com.

Emilie Deliege (E)

University Lille, CHU Lille, Pôle Femme Mère Nouveau-né, Avenue Eugène Avinée, 59000, Lille, France.

Ophélie Mancel (O)

University Lille, CHU Lille, Pôle Femme Mère Nouveau-né, Avenue Eugène Avinée, 59000, Lille, France.

Philippe Dufour (P)

University Lille, CHU Lille, Pôle Femme Mère Nouveau-né, Avenue Eugène Avinée, 59000, Lille, France.

Sophie Vanderstichele (S)

University Lille, CHU Lille, Pôle Femme Mère Nouveau-né, Avenue Eugène Avinée, 59000, Lille, France.

Marielle Roumilhac (M)

University Lille, CHU Lille, Pôle Femme Mère Nouveau-né, Avenue Eugène Avinée, 59000, Lille, France.

Yamina Hammou (Y)

University Lille, CHU Lille, Pôle Femme Mère Nouveau-né, Avenue Eugène Avinée, 59000, Lille, France.

Sophie Carpentier (S)

University Lille, CHU Lille, Pôle Femme Mère Nouveau-né, Avenue Eugène Avinée, 59000, Lille, France.

Rodrigue Dessein (R)

University Lille, EA7366, Recherche Translationelle Relation Hôte-Pathogènes, Faculté de Médecine Pôle Recherche 5 ème étage Ouest, 1 Place de Verdun, 59045, Lille, France.

Damien Subtil (D)

University Lille, EA 2694 : épidémiologie et qualité des soins, pôle recherche aile Est 2ème étage, 59 045 cedex, 1 Place de Verdun, 59 000, Lille, France.
University Lille, CHU Lille, Pôle Femme Mère Nouveau-né, Avenue Eugène Avinée, 59000, Lille, France.

Karine Faure (K)

University Lille, EA7366, Recherche Translationelle Relation Hôte-Pathogènes, Faculté de Médecine Pôle Recherche 5 ème étage Ouest, 1 Place de Verdun, 59045, Lille, France.
University Lille, CHU Lille, Service de Maladies Infectieuses, rue Michel Polonowski, 59000, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH